These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

357 related articles for article (PubMed ID: 23438483)

  • 21. Efficacy, safety and medication cost implications of adalimumab 40 mg weekly dosing in patients with psoriasis with suboptimal response to 40 mg every other week dosing: results from an open-label study.
    Leonardi C; Sobell JM; Crowley JJ; Mrowietz U; Bao Y; Mulani PM; Gu Y; Okun MM
    Br J Dermatol; 2012 Sep; 167(3):658-67. PubMed ID: 22564148
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Maintenance therapy with certolizumab pegol for Crohn's disease.
    Schreiber S; Khaliq-Kareemi M; Lawrance IC; Thomsen OØ; Hanauer SB; McColm J; Bloomfield R; Sandborn WJ;
    N Engl J Med; 2007 Jul; 357(3):239-50. PubMed ID: 17634459
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed.
    Sands BE; Feagan BG; Rutgeerts P; Colombel JF; Sandborn WJ; Sy R; D'Haens G; Ben-Horin S; Xu J; Rosario M; Fox I; Parikh A; Milch C; Hanauer S
    Gastroenterology; 2014 Sep; 147(3):618-627.e3. PubMed ID: 24859203
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adalimumab combined with ciprofloxacin is superior to adalimumab monotherapy in perianal fistula closure in Crohn's disease: a randomised, double-blind, placebo controlled trial (ADAFI).
    Dewint P; Hansen BE; Verhey E; Oldenburg B; Hommes DW; Pierik M; Ponsioen CI; van Dullemen HM; Russel M; van Bodegraven AA; van der Woude CJ
    Gut; 2014 Feb; 63(2):292-9. PubMed ID: 23525574
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis.
    Sandborn WJ; van Assche G; Reinisch W; Colombel JF; D'Haens G; Wolf DC; Kron M; Tighe MB; Lazar A; Thakkar RB
    Gastroenterology; 2012 Feb; 142(2):257-65.e1-3. PubMed ID: 22062358
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Surrogate markers and clinical indices, alone or combined, as indicators for endoscopic remission in anti-TNF-treated luminal Crohn's disease.
    af Björkesten CG; Nieminen U; Turunen U; Arkkila P; Sipponen T; Färkkilä M
    Scand J Gastroenterol; 2012 May; 47(5):528-37. PubMed ID: 22356594
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adalimumab in patients with Crohn's disease--safety and efficacy in an open-label single centre study.
    Seiderer J; Brand S; Dambacher J; Pfennig S; Jürgens M; Göke B; Ochsenkühn T
    Aliment Pharmacol Ther; 2007 Apr; 25(7):787-96. PubMed ID: 17373917
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease.
    Sandborn WJ; Hanauer S; Loftus EV; Tremaine WJ; Kane S; Cohen R; Hanson K; Johnson T; Schmitt D; Jeche R
    Am J Gastroenterol; 2004 Oct; 99(10):1984-9. PubMed ID: 15447761
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety and efficacy of adalimumab for moderate to severe Crohn's disease in children.
    Hyams JS; Griffiths A; Markowitz J; Baldassano RN; Faubion WA; Colletti RB; Dubinsky M; Kierkus J; Rosh J; Wang Y; Huang B; Bittle B; Marshall M; Lazar A
    Gastroenterology; 2012 Aug; 143(2):365-74.e2. PubMed ID: 22562021
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Certolizumab pegol for the treatment of Crohn's disease.
    Sandborn WJ; Feagan BG; Stoinov S; Honiball PJ; Rutgeerts P; Mason D; Bloomfield R; Schreiber S;
    N Engl J Med; 2007 Jul; 357(3):228-38. PubMed ID: 17634458
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of adalimumab on clinical laboratory parameters in patients with Crohn's disease: results from the CHARM trial.
    Rubin DT; Mulani P; Chao J; Pollack PF; Bensimon AG; Yu AP; Ghosh S
    Inflamm Bowel Dis; 2012 May; 18(5):818-25. PubMed ID: 21887727
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of adalimumab in Canadian patients with moderate to severe Crohn's disease: results of the Adalimumab in Canadian SubjeCts with ModErate to Severe Crohn's DiseaSe (ACCESS) trial.
    Panaccione R; Loftus EV; Binion D; McHugh K; Alam S; Chen N; Guerette B; Mulani P; Chao J
    Can J Gastroenterol; 2011 Aug; 25(8):419-25. PubMed ID: 21912766
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adalimumab maintenance therapy for Crohn's disease with intolerance or lost response to infliximab: an open-label study.
    Peyrin-Biroulet L; Laclotte C; Bigard MA
    Aliment Pharmacol Ther; 2007 Mar; 25(6):675-80. PubMed ID: 17311600
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Subgroup analysis of the placebo-controlled CHARM trial: increased remission rates through 3 years for adalimumab-treated patients with early Crohn's disease.
    Schreiber S; Reinisch W; Colombel JF; Sandborn WJ; Hommes DW; Robinson AM; Huang B; Lomax KG; Pollack PF
    J Crohns Colitis; 2013 Apr; 7(3):213-21. PubMed ID: 22704916
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mucosal healing at 3 months predicts long-term endoscopic remission in anti-TNF-treated luminal Crohn's disease.
    af Björkesten CG; Nieminen U; Sipponen T; Turunen U; Arkkila P; Färkkilä M
    Scand J Gastroenterol; 2013 May; 48(5):543-51. PubMed ID: 23477356
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CDP571, a humanised monoclonal antibody to tumour necrosis factor alpha, for moderate to severe Crohn's disease: a randomised, double blind, placebo controlled trial.
    Sandborn WJ; Feagan BG; Radford-Smith G; Kovacs A; Enns R; Innes A; Patel J
    Gut; 2004 Oct; 53(10):1485-93. PubMed ID: 15361500
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adalimumab real-world dosage pattern and predictors of weekly dosing: patients with Crohn's disease in the United States.
    Loftus EV; Pan X; Zurawski P; Mulani P; Chao J
    J Crohns Colitis; 2011 Dec; 5(6):550-4. PubMed ID: 22115373
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial.
    Peyrin-Biroulet L; Reinisch W; Colombel JF; Mantzaris GJ; Kornbluth A; Diamond R; Rutgeerts P; Tang LK; Cornillie FJ; Sandborn WJ
    Gut; 2014 Jan; 63(1):88-95. PubMed ID: 23974954
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adalimumab: in Crohn's disease.
    Plosker GL; Lyseng-Williamson KA
    BioDrugs; 2007; 21(2):125-32; discussion 133-4. PubMed ID: 17402796
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adalimumab dose escalation and dose de-escalation success rate and predictors in a large national cohort of Crohn's patients.
    Baert F; Glorieus E; Reenaers C; D'Haens G; Peeters H; Franchimont D; Dewit O; Caenepeel P; Louis E; Van Assche G;
    J Crohns Colitis; 2013 Mar; 7(2):154-60. PubMed ID: 22537637
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.